SciSparc Ltd.’s stock witnessed an extraordinary surge, skyrocketing over 100% during trading hours, following the announcement of its strengthened international patent portfolio with Clearmind Medicine Inc. This remarkable increase underscores the market’s enthusiastic reception to SciSparc’s innovative strides in developing treatments for central nervous system disorders and rare diseases, leveraging psychedelic-based compounds.
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, announced a strengthening of its international patent portfolio through a collaboration with Clearmind Medicine Inc. This involves filing three patent applications related to novel combinations of psychedelic-based compounds for treating central nervous system disorders and rare diseases. The focus is on proprietary combinations of LSD, psilocybin, DMT, and SciSparc’s CannAmide™. This move, part of ongoing collaborations, aims to enhance the therapeutic potential of these compounds.
Following the announcement of its strengthened international patent portfolio, SciSparc Ltd. has seen a notable spike in its stock price. Investors and traders have responded positively to the news of the patent applications for novel combinations of psychedelic-based compounds, signaling strong market confidence in SciSparc’s innovative approach to treating central nervous system disorders and rare diseases. This surge reflects the market’s optimism about the potential for these new treatments and SciSparc’s position in the burgeoning field of psychedelic-based therapeutics.
